Research

Parion continues to invest in identifying new opportunities to treat unmet needs in diseases where the respiratory innate defense is insufficient. Our research pipeline includes a variety of mechanisms and novel compounds targeting mucus properties, oxidative stress, inflammation and anti-virals. These programs are designed to treat unmet needs in asthma, COPD, non-CF bronchiectasis, cystic fibrosis, IPF and respiratory viral infections.